# US 2019/0376040 A1 · Methods of reprogramming cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376040 A1
- Document ID: US20190376040A1
- Status: Published application
- Kind: A1
- Application number: 16/292,114
- Filed: 2019-03-04
- Published: 2019-12-12
- Earliest claimed: 2008-08-22
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: Douglas A. Melton; Qiao Zhou
- Web page: https://patentgrep.com/patent/US20190376040A1

## CPC

- C12N 5/0676: {Pancreatic cells}
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C12N 2501/60: Transcription factors
- C12N 2510/00: Genetically modified cells
- C12N 2799/022: where the vector is derived from an adenovirus
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic β-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic β-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic β-cell.

## Claims

### Claim at position 1

-52. (canceled)

### Claim 53

A method for the treatment of a subject with diabetes, the method comprising administering a composition comprising an isolated population of pancreatic β-like cells obtained from a population of non-insulin producing cells of endoderm origin by a process comprising increasing the protein expression of at least two transcription factors selected from Ngn3, Pdx1 or MafA, or a functional fragment thereof, in the non-insulin producing cells of endoderm origin.

### Claim 54 (depends on 53)

The method of claim 53, wherein the pancreatic β-like cells are produced from non-insulin producing endoderm cells obtained from the same subject as the composition is administered to.

### Claim 55 (depends on 53)

The method of claim 53, wherein the subject has, or has an increased risk of developing, diabetes.

### Claim 56 (depends on 53)

The method of claim 53, wherein the diabetes is selected from the group consisting of: Type I diabetes, Type II diabetes and pre-diabetes.

### Claim 57 (depends on 53)

The method of claim 53, wherein the subject has, or has an increased risk of developing, a metabolic disorder.

### Claim at position 7

-69. (canceled)
